// App-Quantinova.ai

2205 : A Phase 1b Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders

Researchers

Presenter

  • Alex Sternberg

Principal Investigators

  • Rebecca H. Boucher

  • Helen C Coulthard

  • Manoj Raghavan

  • Dominic J. Culligan

  • Aimee Jackson

  • Catherine Cargo

  • Mike Dennis

  • Marlen Metzner

  • Rachel Moore

  • David Bowen

  • Paresh Vyas

Medical Centers

  • Department of Haematology, Great Western Hospital, Swindon, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Centre for Clinical Haematology - Queen Elizabeth Hospital, Birmingham, United Kingdom,

  • Dept of Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Weatherall Institute of Molecular Medicine and Oxford Cancer Centre, Oxford, United Kingdom

  • Paediatric Haematology,Leeds Teaching Hospitals,Leeds,United Kingdom

  • MRC Molecular Haematology Unit, University of Oxford, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

  • Chronic myelomonocytic leukemia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

  • Eltrombopag

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • ISRCTN05858391

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved